Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease

NCT05771428 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
263
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

AbbVie